Veradermics, Incorporated (NYSE:MANE - Get Free Report) insider Timothy August Durso sold 43,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $107.82, for a total value of $4,690,170.00. Following the transaction, the insider owned 78,142 shares of the company's stock, valued at approximately $8,425,270.44. This trade represents a 35.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Veradermics Price Performance
MANE stock opened at $111.33 on Wednesday. The stock's 50 day moving average is $110.50. The firm has a market capitalization of $4.65 billion and a P/E ratio of -58.59. Veradermics, Incorporated has a twelve month low of $32.00 and a twelve month high of $131.24.
Veradermics (NYSE:MANE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.58). On average, research analysts forecast that Veradermics, Incorporated will post -2.74 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its position in Veradermics stock. Bamco Inc. NY lifted its holdings in Veradermics, Incorporated (NYSE:MANE - Free Report) by 284.8% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 229,581 shares of the company's stock after buying an additional 169,913 shares during the quarter. Bamco Inc. NY owned approximately 0.55% of Veradermics worth $28,225,000 as of its most recent filing with the SEC.
Analyst Ratings Changes
Several equities analysts have recently commented on MANE shares. Needham & Company LLC increased their price target on shares of Veradermics from $136.00 to $164.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Lifesci Capital assumed coverage on Veradermics in a report on Tuesday, June 16th. They issued an "outperform" rating and a $135.00 price objective for the company. Weiss Ratings initiated coverage on Veradermics in a research note on Tuesday, May 26th. They set a "sell (d+)" rating on the stock. B. Riley Financial started coverage on Veradermics in a report on Wednesday, July 15th. They set a "buy" rating and a $170.00 target price on the stock. Finally, Citigroup lifted their target price on Veradermics from $135.00 to $160.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $153.00.
Read Our Latest Report on MANE
About Veradermics
(
Get Free Report)
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
